

# CITATION REPORT

List of articles citing

Hydroxychloroquine in decompensated, treatment-refractory noninsulin-dependent diabetes mellitus. A new job for an old drug?

DOI: 10.7326/0003-4819-112-9-678

Annals of Internal Medicine, 1990, 112, 678-81.

**Source:** <https://exaly.com/paper-pdf/21861823/citation-report.pdf>

**Version:** 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
124	The combined insulin and sulfonylurea therapy in diabetes of elderly people. <b>1991</b> , 13, 245-53		3
123	Mode of action of chloroquine in patients with non-insulin-dependent diabetes mellitus. <b>1991</b> , 260, E897-904		23
122	Steady-state pharmacokinetics of hydroxychloroquine in rheumatoid arthritis patients. <b>1991</b> , 25, 1302-5		17
121	Management of non-insulin-dependent diabetes mellitus. <b>1992</b> , 44 Suppl 3, 29-38		16
120	Round-Table Discussion. <b>1992</b> , 44, 61-65		
119	Type II Diabetes and Syndrome X: Pathogenesis and Glycemic Management. <b>1992</b> , 21, 329-350		16
118	Height and glucose tolerance. <b>1992</b> , 35, 698-9		3
117	Effects of chloroquine on the dyslipidemia of non-insulin-dependent diabetes mellitus. <b>1993</b> , 42, 415-9		21
116	Five-compartment model of insulin kinetics and its use to investigate action of chloroquine in NIDDM. <b>1993</b> , 265, E162-75		22
115	Chloroquine reduces whole body proteolysis in humans. <b>1994</b> , 267, E183-6		6
114	Short-term effects of mepacrine on serum lipids, lipoproteins, and apolipoproteins in patients with non-insulin-dependent diabetes mellitus. <b>1994</b> , 43, 131-4		1
113	Chloroquine does not exert insulin-like actions on human forearm muscle metabolism. <b>1995</b> , 268, E820-4		4
112	Antimalarial Drugs. <b>1995</b> , 4, 219-234		5
111	The use of chloroquine and hydroxychloroquine for non-infectious conditions other than rheumatoid arthritis or lupus: a critical review. <b>1996</b> , 5, 59-64		25
110	Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. <b>1996</b> , 5, 16-22		143
109	Effect of experimental diabetes mellitus and arthritis on the pharmacokinetics of hydroxychloroquine enantiomers in rats. <b>1998</b> , 15, 897-903		21
108	Inhibition of insulin metabolism by hydroxychloroquine and its enantiomers in cytosolic fraction of liver homogenates from healthy and diabetic rats. <b>1999</b> , 64, 325-35		32

107	Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. <b>1999</b> , 160, 736-55	1653
106	Insulin-sparing effect of hydroxychloroquine in diabetic rats is concentration dependent. <b>1999</b> , 77, 118-123	35
105	The use of antimalarials in dermatology. <b>2000</b> , 11, 185-194	2
104	Antimalarials. <b>2001</b> , 19, 147-60, ix	55
103	Antimalarial therapy: a panacea for mild lupus?. <b>2001</b> , 10, 148-51	26
102	Antimalarials in cutaneous lupus erythematosus: mechanisms of therapeutic benefit. <b>2002</b> , 11, 71-81	53
101	The effectiveness of hydroxychloroquine in patients with type 2 diabetes mellitus who are refractory to sulfonylureas--a randomized trial. <b>2002</b> , 55, 209-19	120
100	Antidiabetic and antimalarial biguanide drugs are metal-interactive antiproteolytic agents. <b>2003</b> , 66, 663-77	47
99	Stereoselectivity in the pharmacodynamics and pharmacokinetics of the chiral antimalarial drugs. <b>2003</b> , 42, 1359-82	79
98	Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. <b>2005</b> , 52, 1473-80	261
97	[Antimalarials: an update in rheumatic diseases]. <b>2006</b> , 2, 190-201	8
96	Prevention of cardiovascular disease in patients with rheumatic diseases. <b>2006</b> , 20, 741-56	5
95	Discontinuation rate and factors predictive of the use of hydroxychloroquine in LUMINA, a multiethnic US cohort (LUMINA XL). <b>2006</b> , 15, 700-4	7
94	Current and emerging strategies for the management of sarcoidosis. <b>2007</b> , 8, 1293-311	15
93	Stereoselective determination of hydroxychloro-quine and its major metabolites in human urine by solid-phase microextraction and HPLC. <b>2007</b> , 30, 2351-9	15
92	Cardiovascular risk assessment and treatment in systemic lupus erythematosus. <b>2009</b> , 23, 481-94	26
91	[Antimalarials. A treatment option for every lupus patient!?.] <b>2009</b> , 68, 584, 586-90	4
90	Changes in glycosylated hemoglobin after initiation of hydroxychloroquine or methotrexate treatment in diabetes patients with rheumatic diseases. <b>2010</b> , 62, 3569-73	74

89	Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus. <b>2010</b> , 37, 1136-42	98
88	[Treatment of sarcoidosis]. <b>2011</b> , 32, 109-13	18
87	Clinical research in systemic lupus erythematosus: immediate relevance to clinical practice. <b>2011</b> , 14, 1-5	5
86	Antimalarials and SLE. <b>2011</b> , 1061-1081	0
85	Hypoglycemia induced by hydroxychloroquine in a patient treated for rheumatoid arthritis. <b>2011</b> , 17, 46-7	28
84	Hydroxychloroquine use and decreased risk of diabetes in rheumatoid arthritis patients. <b>2011</b> , 17, 115-20	57
83	Hydroxychloroquine improves insulin sensitivity in obese non-diabetic individuals. <b>2012</b> , 14, R135	65
82	Hydroxychloroquine: from malaria to autoimmunity. <b>2012</b> , 42, 145-53	348
81	[Multimorbidity in elderly rheumatic patients part 2]. <b>2013</b> , 72, 539-46	3
80	Sarcoidosis - a clinically orientated review. <b>2013</b> , 42, 281-9	15
79	Sulphonylurea monotherapy for patients with type 2 diabetes mellitus. <b>2013</b> , CD009008	34
78	Multifaceted effects of hydroxychloroquine in human disease. <b>2013</b> , 43, 264-72	88
77	Carbohydrate metabolism disorders in patients with rheumatoid arthritis and ankylosing spondylitis Impact of treatment. <b>2014</b> , 2, 129-135	
76	Effect of hydroxychloroquine on insulin sensitivity and lipid parameters in rheumatoid arthritis patients without diabetes mellitus: a randomized, blinded crossover trial. <b>2014</b> , 66, 1246-51	45
75	Effect of methotrexate use and erythrocyte methotrexate polyglutamate on glycosylated hemoglobin in rheumatoid arthritis. <b>2014</b> , 66, 2026-36	12
74	Efficacy and safety of hydroxychloroquine in the treatment of type 2 diabetes mellitus: a double blind, randomized comparison with pioglitazone. <b>2014</b> , 30, 1257-66	60
73	A favorable effect of hydroxychloroquine on glucose and lipid metabolism beyond its anti-inflammatory role. <b>2014</b> , 5, 77-85	52
72	Hydroxychloroquine: a multifaceted treatment in lupus. <b>2014</b> , 43, e167-80	101

71	Prevention and management of co-morbidities in SLE. <b>2014</b> , 43, e187-95	21
70	Steroid-induced diabetes mellitus in systemic lupus erythematosus patients: analysis from a Malaysian multi-ethnic lupus cohort. <b>2015</b> , 18, 541-7	16
69	Re: Pareek A, Chandurkar N, Thomas N, et al. Efficacy and safety of hydroxychloroquine in the treatment of type 2 diabetes mellitus: a double blind, randomized comparison with pioglitazone. <i>Curr Med Res Opin</i> 2014;30:1257-66. <b>2015</b> , 31, 1087-92	
68	WITHDRAWN: Sulphonylurea monotherapy for patients with type 2 diabetes mellitus. <b>2015</b> , CD009008	0
67	Antidiabetogenic effects of hydroxychloroquine on insulin sensitivity and beta cell function: a randomised trial. <b>2015</b> , 58, 2336-43	62
66	Hydroxychloroquine Blood Levels in Systemic Lupus Erythematosus: Clarifying Dosing Controversies and Improving Adherence. <b>2015</b> , 42, 2092-7	98
65	Efficacy and safety of fixed dose combination of atorvastatin and hydroxychloroquine: a randomized, double-blind comparison with atorvastatin alone among Indian patients with dyslipidemia. <b>2015</b> , 31, 2105-17	22
64	Hydroxychloroquine for the prevention of recurrent cardiovascular events in myocardial infarction patients: rationale and design of the OXI trial. <b>2017</b> , 3, 92-97	22
63	Drug approvals in India. <b>2016</b> , 4, 19-20	2
62	Hydroxychloroquine, a promising choice for coronary artery disease?. <b>2016</b> , 93, 5-7	15
61	Anti-malarials: Are There Benefits Beyond Mild Disease?. <b>2016</b> , 2, 1-12	5
60	Immune-Modulating Therapy for Rheumatologic Disease: Implications for Patients with Diabetes. <b>2016</b> , 16, 91	3
59	Anti-inflammatory Agents in the Treatment of Diabetes and Its Vascular Complications. <b>2016</b> , 39 Suppl 2, S244-52	134
58	Favorable outcomes of hydroxychloroquine in insulin resistance may be accomplished by adjustment of the endothelial dysfunction as well as the skewed balance of adipokines. <b>2016</b> , 118, 560-573	20
57	Hydroxychloroquine hindering of diabetic isletopathy carries its signature on the inflammatory cytokines. <b>2016</b> , 47, 183-93	14
56	Cooling down inflammation in type 2 diabetes: how strong is the evidence for cardiometabolic benefit?. <b>2017</b> , 55, 360-365	25
55	Cardiovascular disease in rheumatoid arthritis: medications and risk factors in China. <b>2017</b> , 36, 1023-1029	10
54	Clinical significance of lipid profile in systemic lupus erythematosus patients: Relation to disease activity and therapeutic potential of drugs. <b>2017</b> , 39, 93-98	7

53	Hydroxychloroquine: Looking into the Future. <b>2017</b> , 24, 369-375	4
52	Desirable and Adverse Effects of Antiinflammatory Agents on the Heart. <b>2017</b> , 617-643	0
51	Targeting autophagy in obesity: from pathophysiology to management. <b>2018</b> , 14, 356-376	166
50	Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a systematic review and meta-analysis. <b>2018</b> , 77, 98-103	117
49	Protective Effects of Hydroxychloroquine against Accelerated Atherosclerosis in Systemic Lupus Erythematosus. <b>2018</b> , 2018, 3424136	35
48	Current and Future Use of Chloroquine and Hydroxychloroquine in Infectious, Immune, Neoplastic, and Neurological Diseases: A Mini-Review. <b>2018</b> , 38, 653-671	152
47	Association between hydroxychloroquine levels and disease activity in a predominantly Hispanic systemic lupus erythematosus cohort. <b>2019</b> , 28, 862-867	14
46	NURR1 activation in skeletal muscle controls systemic energy homeostasis. <b>2019</b> , 116, 11299-11308	20
45	Issues for the management of people with diabetes and COVID-19 in ICU. <b>2020</b> , 19, 114	23
44	The COVID-19 pandemic and diabetes mellitus. <b>2020</b> , 5, e200-e205	3
43	New Benefits of Hydroxychloroquine in Pregnant Women with Systemic Lupus Erythematosus: A Retrospective Study in a Tertiary Centre. <b>2020</b> , 42, 705-711	0
42	COVID-19 prevention and treatment: A critical analysis of chloroquine and hydroxychloroquine clinical pharmacology. <b>2020</b> , 17, e1003252	55
41	SARS-CoV-2 (COVID-19) and the Endocrine System. <b>2020</b> , 4, bvaa144	28
40	Antihyperglycemic properties of hydroxychloroquine in patients with diabetes: Risks and benefits at the time of COVID-19 pandemic. <b>2020</b> , 12, 659-667	19
39	Issues of Cardiovascular Risk Management in People With Diabetes in the COVID-19 Era. <b>2020</b> , 43, 1427-1432	47
38	Dissecting the interaction between COVID-19 and diabetes mellitus. <b>2020</b> , 11, 1104-1114	22
37	SARS-CoV-2 disease severity and diabetes: why the connection and what is to be done?. <b>2020</b> , 17, 21	30
36	Hypoglycemia Induced by Hydroxychloroquine Sulfate in a Patient Treated for Connective Tissue Disease Without Diabetes Mellitus. <b>2020</b> , 42, 940-945	4

35	COVID-19 and diabetes management: What should be considered?. <b>2020</b> , 163, 108151		63
34	Efficacy and safety of hydroxychloroquine as add-on therapy in uncontrolled type 2 diabetes patients who were using two oral antidiabetic drugs. <b>2021</b> , 44, 481-492		11
33	Hydroxychloroquine, COVID-19 and diabetes. Why it is a different story. <b>2021</b> , 37, e3379		10
32	Safety of hydroxychloroquine in COVID-19 and other diseases: a systematic review and meta-analysis of 53 randomized trials. <b>2021</b> , 77, 13-24		9
31	The effects of hydroxychloroquine on insulin sensitivity, insulin clearance and inflammation in insulin-resistant adults: A randomized trial. <b>2021</b> , 23, 1252-1261		4
30	Diabetes mellitus in combination with COVID-19: modern views on therapy. <b>2021</b> , 8-20		
29	Coronavirus disease 2019 (COVID-19) in a Chinese renal transplant recipient: a case report. <b>2021</b> , 10, 2140-2148		1
28	A systematic review and meta-analysis of the safety of Hydroxychloroquine in a randomized controlled trial and observational studies. <b>2021</b> ,		
27	[Multidisciplinary nutritional consensus on assessment and nutritional dietary treatment in patients with chronic kidney disease and SARS-CoV-2 infection]. <b>2021</b> , 41, 453-460		1
26	Effects of Hydroxychloroquine on endothelial function in elderly with sleep apnea (HOLD): study protocol for a randomized clinical trial. <b>2021</b> , 22, 638		0
25	Antimalarial drugs (and lupus). <b>2021</b> , 601-609		
24	Molekulare Grundlagen der Behandlung rheumatischer Erkrankungen. <b>2003</b> , 237-253		1
23	ANTIMALARIAL AGENTS AND LUPUS. <i>Rheumatic Disease Clinics of North America</i> , <b>1994</b> , 20, 243-263	2.4	96
22	Hydroxychloroquine as a glucose lowering drug. <i>BMJ Case Reports</i> , <b>2011</b> , 2011,	0.9	16
21	Hydroxychloroquine: a diabetic drug in disguise?. <i>BMJ Case Reports</i> , <b>2009</b> , 2009,	0.9	8
20	Real-World Clinical Effectiveness and Tolerability of Hydroxychloroquine 400 Mg in Uncontrolled Type 2 Diabetes Subjects who are not Willing to Initiate Insulin Therapy (HYQ-Real-World Study). <i>Current Diabetes Reviews</i> , <b>2019</b> , 15, 510-519	2.7	16
19	Comparison of Efficacy and Safety of Hydroxychloroquine and Tenueligliptin in Type 2 Diabetes Patients who are Inadequately Controlled with Glimpiride, Metformin and Insulin therapy: A Randomized Controlled Trial with Parallel Group Design. <b>2017</b> , 2, 033-040		4
18	The effect of hydroxychloroquine on glucose control and insulin resistance in the prediabetes condition. <i>Advanced Biomedical Research</i> , <b>2016</b> , 5, 145	1.2	15

17	Multidisciplinary nutritional consensus on assessment and nutritional dietary treatment in patients with chronic kidney disease and SARS-CoV-2 infection[[es]]Consenso multidisciplinar sobre la valoración y el tratamiento nutricional y dietético en pacientes con enfermedad renal crónica e infección por SARS-CoV-2. Consenso de nutrición en enfermedad renal crónica e infección por SARS-CoV-2. <i>Nefrología</i> , <b>2021</b> , 41, 453-453	0.4	78
16	Sarcoidosis. <b>2001</b> , 193-220		
15	H. <b>1999</b> , 611-657		
14	Management of Routine Surgery in Diabetes. <b>2019</b> , 133-161		
13	Effectiveness and Safety of Hydroxychloroquine compared to Tenelegliptin in uncontrolled T2DM patients as add-on Therapy. <i>Journal of the ASEAN Federation of Endocrine Societies</i> , <b>2019</b> , 34, 87-91	0.5	2
12	Hydroxychloroquine as Oral Antidiabetic Agent During Coronavirus Pandemic. <i>Global Journal of Infectious Diseases and Clinical Research</i> , <b>2020</b> , 6, 006-008	0.2	
11	Diabetes and COVID-19: A Review. <i>Journal of the ASEAN Federation of Endocrine Societies</i> , <b>2020</b> , 35, 40-48.	0.5	2
10	Antipalúdicos de síntesis en dermatología. <i>EMC - Dermatología</i> , <b>2020</b> , 54, 1-11	0.1	
9	Glycemic efficacy and safety of hydroxychloroquine in type 2 diabetes mellitus: A systematic review and meta.analysis of relevance amid the COVID-19 pandemic. <i>International Journal of Noncommunicable Diseases</i> , <b>2020</b> , 5, 184	0.6	0
8	Systematic review and meta-analysis of the safety of chloroquine and hydroxychloroquine from randomized controlled trials on malarial and non-malarial conditions. <i>Systematic Reviews</i> , <b>2021</b> , 10, 294	3	0
7	Diabetes Mellitus and Osteoporosis Correlation: Challenges and Hopes. <i>Current Diabetes Reviews</i> , <b>2020</b> , 16, 984-1001	2.7	3
6	COVID-19: <b>2021</b> , 26, 227-247		
5	Efficacy and safety of hydroxychloroquine for managing glycemia in type-2 diabetes: A systematic review and meta-analysis.. <i>Journal of Postgraduate Medicine</i> , <b>2022</b> , 68, 85-92	0.8	0
4	Diabetes-Modifying Antirheumatic Drugs: The Roles of DMARDs as Glucose-Lowering Agents. <i>Medicina (Lithuania)</i> , <b>2022</b> , 58, 571	3.1	1
3	Immunomodulatory and immunosuppressive therapies in cardiovascular disease and type 2 diabetes mellitus: A bedside-to-bench approach.. <i>European Journal of Pharmacology</i> , <b>2022</b> , 925, 174998	5.3	
2	Treating diabetes with combination of phosphodiesterase 5 inhibitors and hydroxychloroquine: possible prevention strategy for COVID-19?.		0
1	Hydroxychloroquine and Cardiovascular Events in Patients with Rheumatoid Arthritis.		0